scispace - formally typeset
Search or ask a question

Answers from top 9 papers

More filters
Papers (9)Insight
Also, unlike DNA‐based vaccines, there is little danger of incorporation of RNA sequences into the host genome.
Like other types of nucleic acid vaccines, mRNA vaccines have the potential to combine the positive attributes of live attenuated vaccines while obviating many potential safety limitations.
As new cancer antigens come to the forefront with novel RNA encapsulation and targeting techniques, RNA vaccines may prove to be a vital, safe and robust method to initiate patient-specific anti-tumor efficacy.
Therefore, RNA adjuvants have broad applicability and can be used with all conventional vaccines to improve vaccine efficacy qualitatively and quantitively.
Naked, non-infectious, self-replicating RNA may be an excellent candidate for the development of new cancer vaccines.
We also identified altered expression of these lncRNAs in RNA-sequencing (RNA-seq) data from a cohort of children following immunization with intranasal live attenuated influenza vaccine, suggesting a common role across several diverse vaccines.
From this we conclude that sa-RNA is a promising platform for vaccines against viral diseases.
This suggests that protein-based vaccines formulated using RNA adjuvant function as live-attenuated vaccines.
Journal ArticleDOI
22 Jun 2012-Vaccine
150 Citations
Nucleic acid vaccines consisting of plasmid DNA, viral vectors or RNA may change the way the next generation vaccines are produced, as they have the potential to combine the benefits of live-attenuated vaccines, without the complications often associated with live-attenuated vaccine safety and manufacturing.